Investor Presentaiton

69 69 Q2-23 Health $25M Gross New Contract Signings Revenues (in millions of $) 45 40 39 40 40 $681M Backlog Gross Profit & Margin (in millions of $, except margin) -4% Organic Growth -% Acquisitive Growth Adj. EBITDA¹ & Margin¹ (in millions of $, except margin) 44 8.0 11.3 7.2 10.6 10.0 6.5 9.1 9.6 6.0 6.4 17.7% 16.4% 16.1% 15.9% 25.4% 24.2% 15.1% 25.0% 23.6% 22.9% Q2-22 Q3-22 Q4-22 Q1-23 Q2-23 Q2-22 Q3-22 Q4-22 Gross Profit Q1-23 Gross Margin Q2-23 Q2-22 Q3-22 Q4-22 Q1-23 Q2-23 Adj. EBITDA Adj. EBITDA Margin 1) This is a non-GAAP measure. Please refer to the MD&A. Impacted by lower COVID-19 related business of $8 million, or 19%, over Q2-22 40 YEARS OF CALIAN

View entire presentation